– Bayer and the Broad Institute today announced that they have extended their research collaboration of 10 years by an additional five years, to further advance findings in human genomics research in cardiovascular diseases. The expanded agreement will focus on joint precision cardiology target identification, leveraging the established human cardiomyocyte platform to rapidly validate observations, and discovery of novel therapeutic approaches..

– 拜耳和博德研究所今天宣布，他们将把长达十年的研究合作再延长五年，以进一步推动心血管疾病领域的人类基因组学研究成果。扩大的协议将专注于联合精准心脏病学靶点识别，利用已建立的人类心肌细胞平台快速验证观察结果，并发现新的治疗方法。

Current efforts are directed to develop potential treatment options for patients with specific forms of cardiovascular disease such as dilated cardiomyopathy (DCM), amongst others. DCM is a type of heart disease characterized by the enlargement of the heart's chambers, which leads to a decreased ability to pump blood effectively.

当前的努力方向是为患有特定类型心血管疾病的患者开发潜在的治疗方案，例如扩张型心肌病 (DCM) 等。DCM 是一种心脏病，其特征是心脏腔室扩大，导致泵血能力下降。

This condition can result in heart failure and other complications if left untreated..

这种状况如果未经治疗，可能导致心力衰竭和其他并发症。

Established in 2013, this longstanding collaboration combines the Broad Institute’s extensive expertise in genomics and biology with Bayer’s in-depth experience in small, chemically manufactured molecules and biologics drug discovery to advance drug discovery research for novel cardiovascular therapeutics.

成立于2013年，这一长期合作结合了博德研究所广泛的基因组学和生物学专业知识，以及拜耳在小型化学制造分子和生物制品药物发现方面的深厚经验，以推动新型心血管治疗药物的发现研究。

This strategic research alliance already has resulted in a number of joint publications and conference presentations, and it has paved the way for Bayer's announcement in May 2025 regarding the initiation of a Phase I study with its investigational highly selective G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor which has a potential to help control the electrical activity of heart cells in patients with atrial fibrillation (AFib)..

这一战略性研究联盟已经促成了多篇联合出版物和会议报告，并为拜耳公司于2025年5月宣布启动一项针对其研究中的高选择性G蛋白偶联内向整流钾通道4（GIRK4）抑制剂的I期研究铺平了道路，该抑制剂有望帮助控制心房颤动（AFib）患者的心脏细胞电活动。

“We are constantly evaluating novel approaches to treat cardiovascular diseases that affect millions of people worldwide. Our shared commitment is to explore novel therapeutic targets and modalities in various cardiovascular and renal diseases to help deliver new treatment options to patients in need,” said Andrea Haegebarth, Ph.D., Global Head of Research and Early Development for Cardiovascular, Renal, and Immunology at Bayer’s Pharmaceuticals Division.

“我们一直在不断评估治疗影响全球数百万人的心血管疾病的新方法。我们共同的承诺是探索各种心血管和肾脏疾病中的新治疗靶点和模式，以帮助为有需要的患者提供新的治疗选择，”拜耳制药部门心血管、肾脏和免疫学全球研究与早期开发负责人安德烈亚·黑格巴特博士表示。

“The first joint therapeutic project entered the clinic last month and we are excited to collaborate further with the esteemed scientists at the Broad Institute to identify and develop disease-modifying therapeutics treating underlying causes of cardiovascular diseases.”.

“第一个联合治疗项目于上个月进入临床，我们很高兴与博德研究所的杰出科学家们进一步合作，识别并开发治疗心血管疾病根本原因的疾病修饰疗法。”

“I am delighted to see Broad and Bayer continue this fruitful collaboration in cardiovascular research,” said Todd Golub, director and founding core member of the Broad Institute. “By working together, Broad and Bayer are able to make advances that neither organization could make on its own.”

“我很高兴看到博德研究所和拜耳在心血管研究领域继续这一富有成效的合作，”博德研究所所长兼创始核心成员托德·戈卢布表示。“通过合作，博德研究所和拜耳能够取得单凭任何一方都无法实现的进展。”

Academic collaborations are integral to Bayer's research and development strategy, aimed at delivering innovative treatment solutions to patients, particularly in areas with significant unmet medical needs, such as cardiovascular health. Bayer’s strategic focus in cardiovascular research emphasizes precision drug development, facilitating the rapid identification of the most promising targets and commercially viable programs..

学术合作是拜耳研发战略的重要组成部分，旨在为患者提供创新的治疗方案，特别是在心血管健康等存在重大未满足医疗需求的领域。拜耳在心血管研究中的战略重点强调精准药物开发，促进快速识别最有前景的靶点和商业上可行的项目。

Bayer with its Bayer Research & Innovation Center (BRIC) is closely located to the Broad Institute in Kendall Square, Cambridge, MA. BRIC houses a center of precision oncology research as well as an experienced team of scientists focused on research and early development for developing precision cardiovascular, renal, and immunology therapeutics.

拜耳及其拜耳研究与创新中心 (BRIC) 靠近位于马萨诸塞州剑桥市肯德尔广场的布罗德研究所。BRIC 拥有一个精准肿瘤学研究中心，以及一支专注于研究和早期开发精准心血管、肾脏和免疫学治疗的经验丰富的科学家团队。

BRIC is also home to Bayer Co.Lab Cambridge which is part of a pioneering global network of life science incubators focused on disruptive innovation and scientific breakthroughs. .

BRIC 还拥有拜耳剑桥合作实验室，该实验室是全球生命科学孵化器先锋网络的一部分，专注于颠覆性创新和科学突破。

Financial details have not been disclosed.

财务细节尚未披露。

About Bayer’s Commitment in Cardiovascular Diseases

关于拜耳在心血管疾病方面的承诺

Bayer is a leader in cardiology and is advancing a portfolio of innovative treatments in cardiovascular (CV) diseases of high unmet medical need. The strategy is to unlock the strong potential of the future CV market by transforming Bayer’s portfolio into precision cardiology, addressing the high CV disease burden, and driving the long-term growth.

拜耳是心脏病学领域的领导者，正在推进一系列针对高未满足医疗需求的心血管（CV）疾病创新治疗方案。其战略是通过将拜耳的产品组合转型为精准心脏病学，解决沉重的心血管疾病负担，并推动长期增长，从而释放未来心血管市场的巨大潜力。

Bayer’s portfolio already includes several innovative products as well as compounds in various stages of preclinical and clinical development..

拜耳的产品组合已经包括几种创新产品，以及处于临床前和临床开发不同阶段的化合物。

About Bayer

关于拜耳

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population.

拜耳是一家在医疗保健和营养等生命科学领域拥有核心竞争力的全球性企业。秉承“人人健康，无饥饿”的使命，公司的产品和服务旨在帮助人类和地球繁荣发展，支持应对不断增长和老龄化的全球人口所带来的重大挑战。

Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros.

拜耳致力于通过其业务推动可持续发展并产生积极影响。同时，集团旨在通过创新和增长提高盈利能力并创造价值。拜耳品牌在全球范围内代表信任、可靠性和质量。在2024财年，该集团拥有约93,000名员工，销售额达466亿欧元。

R&D expenses amounted to 6.2 billion euros.

研发费用总计达62亿欧元。